Insight

Getting integration right in biotech acquisitions

It takes a delicate balance of control and freedom to pursue innovation

Frank Schropfer

Frank Schropfer

Principal, Mergers & Acquisitions , KPMG US

+1 703-286-6856

Jeff Stoll

Jeff Stoll

Principal, National Strategy Life Sciences Leader, KPMG US

+1 617-988-1000

Christopher Wienand

Christopher Wienand

Director Advisory, Strategy, KPMG US

+1 917-455-4955

Biotech acquisitions can bring innovation and entrepreneurial energy to big pharma companies. But for these deals to pay off, acquirers need to align the entire organization on how to strike the right balance between independence and integration. Too much control can mean too little innovation—too little creates unmitigated risks. Preparing a customized roadmap allows acquirers to sustain the target’s scientific entrepreneurship and move the newly acquired clinical pipeline towards full commercial potential. Before you consider a biotech deal read this paper—and avoid the integration pitfalls.